BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 1 day ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 1 day ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 1 day ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 1 day ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 1 day ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 1 day ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 5 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
Market News

Obalon Therapeutics (NASDAQ: OBLN): Q3 2019 Earnings Snapshot

— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected. — Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier — Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. […]

$OBLN November 8, 2019 1 min read
Alphastreet Vertex Pharma Q4 2025 Earnings Results
NYSE
$OBLN · Earnings

— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected. — Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier — Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. […]

· November 8, 2019

— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected.

— Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier

— Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. $1.2 million loss expected

— Cost of revenue was $0.4 million, down from $1.4 million in the same period of last year

— Research and development expense declined sharply to $1.2 million from $2.4 million last year

ADVERTISEMENT

—  Opened the first company-owned retail treatment center, the Obalon Center for Weight Loss

— Raised $16.6 million in gross proceeds from an equity offering

— Promoted William Plovanic to President and CEO; promoted Nooshin Hussainy to CFO

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

ADVERTISEMENT